Observational study of patients with Multiple Sclerosis in Switzerland
Official title: Clinnova-MS: a Prospective Cohort Study of Patients With Multiple Sclerosis: A Trans-Regional Digital Health Effort Unlocking the Potential of Artificial Intelligence and Data Science in Health Care (Switzerland)
Run by University Hospital, Basel, Switzerland · NCT06526364 · Data updated 2026-11-12
This study is trying to find out more about the early signs of Multiple Sclerosis and how it changes over time by looking at health data from patients in Switzerland.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | University Hospital, Basel, Switzerland Academic / other |
| Locations | 1 site (Basel) |
| Status | Recruiting |
| Started | December 10, 2024 |
| Main results expected | June 2029 |
| Study ends | June 2029 |
| Registry record updated | December 26, 2025 |
| Trial ID | NCT06526364 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older diagnosed with any form of MS within the first three years of disease onset or those transitioning to progressive MS.
✕Probably not a fit
Patients with advanced stages of MS or those not enrolled in the Swiss MS cohort study may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational cohort study, part of the Clinnova programme, aims to identify clinical imaging and omics characteristics associated with early Multiple Sclerosis (MS) and the transition to progressive MS. It will also investigate digital biomarkers for continuous clinical monitoring of patients. Up to 100 patients with early MS or transitioning to progressive MS will be recruited from the Swiss MS cohort study in Basel, with a total target of at least 800 patients across multiple centers. The study focuses on collecting standardized digital health data to enable detailed phenotyping of patients.
Why it matters
Potential benefit: If successful, this study could lead to improved monitoring and personalized treatment strategies for patients with Multiple Sclerosis.
How similar studies have gone: Other studies have shown promise in using digital tools for monitoring MS, but this approach is part of a novel initiative within the Clinnova programme.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥18 * Participants are willing and able to comply with the protocol, including undergoing data and samples collection as well as study visits and examinations. * Signed informed consent form * In possession of a Healios+Me app compatible smartphone (iOS/Android) * Corrected close visual acuity of ≥0.5 * Hand motor skills sufficient for using a smartphone * Ability to follow the study procedures * Diagnosed with MS according to the revised McDonald criteria 2017, all clinical forms inclusive (clinically isolated syndrome, RRMS, SPMS, PPMS) AND early disease stages (\< 3 years) OR transitioning phase to progressive disease as evaluated based on Expanded Disability Status Scale (EDSS). * Enrolled in the SMSC at University Hospital Basel There are no specific exclusion criteria.
Where it's running
-
Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB)
Basel, Switzerland Recruiting
Study contacts
- Principal investigator: Cristina Granziera, Prof. — Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB)
- Study coordinator: Bebeka Cosandey (Clinnova:Scientific Project Lead), PhD
- Email: bebeka.cosandey@usb.ch
- Phone: +41 79 961 26 31
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Investigating risk factors for disability progression in Multiple Sclerosis
This study is trying to find out what factors might make disability get worse in people with Multiple Sclerosis by looking at their medical history and MRI scans.
-
Brief low-oxygen breathing to boost nerve plasticity and arm strength in MS
This will see if brief bouts of low-oxygen breathing (acute intermittent hypoxia) can quickly improve arm and hand strength and nerve signaling in people with relapsing-remitting MS who have arm weakness.
-
Breathing low oxygen levels to improve strength in people with multiple sclerosis
This study is testing if short periods of low oxygen can help people with multiple sclerosis get stronger and improve their brain's ability to control movement.
-
Anti-CD19 CAR-T for non-relapsing progressive multiple sclerosis
This Phase 1 trial will test whether a single infusion of KYV-101 (anti-CD19 CAR-T cells) is safe and can slow worsening in adults with non-relapsing progressive MS.
-
Using the Cionic Neural Sleeve to improve mobility in people with multiple sclerosis
This study is testing if wearing the Cionic Neural Sleeve can help people with multiple sclerosis walk better and improve their overall mobility.
-
Cladribine treatment for non-active progressive multiple sclerosis
This study is testing whether a new treatment called cladribine can help people with non-active progressive multiple sclerosis feel better and slow down their disease.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.